Dr. Martin D. Madaus is a serial global healthcare CEO, board member, investor and strategy consultant with over 30 years of experience in the Diagnostics and Life Science Tools Industry. He currently works for The Carlyle Group as an Operating Executive and serves as a director on several public and private companies.

He was Chairman and Chief Executive Officer at Ortho-Clinical Diagnostics, Inc. (OCD) from June 2015 until February of 2019 leading the carve-out from JNJ and the business turnaround.

Prior to joining Ortho, Dr. Madaus served as Executive Chairman of Quanterix Corporation, and as Senior Healthcare Advisor to the Carlyle Group.

He was Chairman, President and Chief Executive Officer of Millipore Corporation (NYSE: MIL) from January 2005 to July 2010. In addition, Dr. Madaus was President and Chief Executive Officer of Roche Diagnostics Corporation North America from 2000 to 2004. Prior to that, he served as Vice President of Business Development for Roche Molecular Diagnostics, and served as the President of Roche Diagnostics Canada.

Dr. Madaus started his career in the diagnostics Industry in 1989 at Boehringer Mannheim, Germany and served in various product management, marketing and general management roles in Germany, the United States and Canada.

Dr. Madaus received a Doctor of Veterinary Medicine degree from the University of Munich in Germany and a PhD in Veterinary Medicine from the Veterinary School of Hanover in Germany.

Current boards: Repligen Corp. (NASDAQ: RGEN), Azenta Life Sciences (NASDAQ: AZTA), Hologic (NASDAQ: HLGC), Emulate Bio, Unchained Labs, Syntis Bio.